Capivasertib is a novel, highly potent, selective ATP-competitive pan-AKT kinase inhibitor that exerts similar activity against the three isoforms AKT1, AKT2 and AKT3. Positive data have emerged from early-phase trials, and several phase 3 trials are now underway. These phase 3 trials could provide the basis for regulatory approval of capivasertib in combination with fulvestrant as second or later-line treatment for metastatic HR-positive/HER2-negative breast cancer and in combination with paclitaxel as first-line treatment for locally advanced or metastatic triple-negative breast cancer.
Originating from a collaboration between AstraZeneca, Astex Pharmaceuticals Inc, the Institute of Cancer Research and Cancer Research Technology, capivasertib has shown promising results in early-phase trials, with clinical benefit to patients irrespective of their PIK3CA/AKT1/PTEN mutational status:
Patents estimated to expire beginning in 2028
Access global intelligence, advanced analytics and global experts from Clarivate.